Mr. Speaker, I also share my colleague's objective of ensuring that vulnerable Canadians have access to pharmaceuticals. We can do that.
I am just concerned about examples of nationalization of pharmaceutical care having unintended consequences, as we saw with the OHIP+ program in Ontario, where 2.1 million Ontarians ended up, with the elimination of their privately funded system, having worse levels of care than they did before. They did not have access to drugs that they needed.
Has the member given any thought to that potentially unintended consequence of the bill and how he would mitigate that?